Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGIK: GIK Therapy for Muscle Trauma in Lower Extremity Fractures
NCT05627479Phase 2Withdrawn
- Sponsor
- NYU Langone Health
- Start
- Dec 2024
- Primary completion
- Jan 2026
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sodium potassium magnesium calcium and glucose injection, human insulin and potassium phosphates injection in femoral shaft fracture and tibial shaft fracture (2 arms), sponsored by NYU Langone Health. Primary endpoint: Peak Creatine Kinase Concentration. Planned start Dec 2024; status: withdrawn.
02
Drugs
sodium potassium magnesium calcium and glucose injectionhuman insulinpotassium phosphates injection
03
Conditions
femoral shaft fracturetibial shaft fracture
Beyond the preview
Go deeper on NCT05627479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05627479.